A staff member of a hospital fills prescriptions of traditional Chinese medicine for patients, May 26, 2019. (PHOTO / XINHUA)

BEIJING - An antiviral traditional Chinese medicine composition has been awarded patents by Japan and the United States successively, said a Chinese pharmaceutical company.

The antiviral TCM composition has been proved effective against influenza A virus, HIN1, and Zika virus among others by researches from home and abroad

The medicine is a composition of effective components extracted from TCM raw materials, and has obvious broad-spectrum antiviral effects, said Jia Hongzhang, founder of the Beijing pharmaceutical company Hongtianli.

ALSO READ: TCM treatment recognized by BRI countries

The composition has been proved effective against influenza A virus, HIN1, and Zika virus among others by researches from home and abroad.

The research of the composition's effect mechanism against COVID-19 has also been carried out recently.

READ MORE: TCM plays big role in tackling Delta strain

The patent of the medicine composition was registered by the Japan Patent Office on Jan 13, 2022, and it was awarded the United States Patent on Feb 1, 2022, according to Jia.